NASDAQ:VCEL - Vericel Stock Price, Forecast & News

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel Corp (NASDAQ:VCEL) announced its earnings results on Tuesday, November, 5th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.09. The biotechnology company earned $30.50 million during the quarter, compared to analysts' expectations of $26.84 million. Vericel had a negative net margin of 12.68% and a positive return on equity of 3.66%. The firm's quarterly revenue was up 35.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.02) earnings per share. View Vericel's Earnings History.

Vericel is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Vericel.

4 brokerages have issued twelve-month price targets for Vericel's shares. Their forecasts range from $17.92 to $32.00. On average, they anticipate Vericel's share price to reach $23.23 in the next year. This suggests a possible upside of 24.7% from the stock's current price. View Analyst Price Targets for Vericel.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.

News coverage about VCEL stock has been trending extremely negative on Friday, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vericel earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Vericel.

Some companies that are related to Vericel include Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Regenxbio (RGNX), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Alector (ALEC), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), Fate Therapeutics (FATE), Krystal Biotech (KRYS) and Precision BioSciences (DTIL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Synergy Pharmaceuticals (SGYP), Momo (MOMO), Exelixis (EXEL), Novavax (NVAX), NVIDIA (NVDA), Dynavax Technologies (DVAX), Amarin (AMRN), Verastem (VSTM), Progenics Pharmaceuticals (PGNX) and TG Therapeutics (TGTX).

Vericel's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.25%), Emerald Advisers LLC (1.71%), GW&K Investment Management LLC (1.62%), Russell Investments Group Ltd. (1.04%), Calamos Advisors LLC (0.92%) and Perkins Capital Management Inc. (0.90%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman. View Institutional Ownership Trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including SG Capital Management LLC, State Street Corp, Squarepoint Ops LLC, Perkins Capital Management Inc., Barclays PLC, Emerald Advisers LLC, Essex Investment Management Co. LLC and Alps Advisors Inc.. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman. View Insider Buying and Selling for Vericel.

VCEL stock was acquired by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, SG Americas Securities LLC, California Public Employees Retirement System, Granahan Investment Management Inc. MA, Insight Wealth Strategies LLC, BBVA USA Bancshares Inc., Boston Advisors LLC and Conestoga Capital Advisors LLC. View Insider Buying and Selling for Vericel.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $18.63.

Vericel has a market capitalization of $832.67 million and generates $90.86 million in revenue each year. The biotechnology company earns $-8,140,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Vericel employs 216 workers across the globe.View Additional Information About Vericel.

The official website for Vericel is http://www.vcel.com/.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]